Harvett, do you realise that to succeed they need to pass all phases of human trials over several years and than be approved by the relevant bodies as a cure to cancer or an improvement on the present chemotherapy treatment
Many new drug candidates pass Phase 1 and 2 and fail Phase 3
The probabilities for success for all biotech techs in oncology has always been well under 1%